Triple
T22796802
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | LOXO-195 |
E564270
|
entity |
| Predicate | developedBy |
P73
|
FINISHED |
| Object | Loxo Oncology |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Loxo Oncology | Statement: [LOXO-195, developedBy, Loxo Oncology]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Loxo Oncology Context triple: [LOXO-195, developedBy, Loxo Oncology]
-
A.
Loxo Oncology (acquired)
chosen
Loxo Oncology (acquired) is a biotechnology company focused on developing targeted cancer therapies, particularly for tumors driven by specific genetic alterations.
-
B.
Guardant Health
Guardant Health is a precision oncology company specializing in blood-based liquid biopsy tests to detect, monitor, and guide treatment of cancer.
-
C.
United Therapeutics
United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other serious cardiopulmonary conditions.
-
D.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
E.
Seagen
Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
Created at: April 17, 2026, 3:30 p.m.